Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018.

After the successful divestment of Emapalumab related activities, we now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    1999
  • Number of employees in Switzerland
    50-149
Key business